ApoGlyx contributes to the United Nations 2030 Agenda for Sustainable Development
ApoGlyx has joined the Educate All initiative led by the United Nations Institute for Training and Research (Unitar) and microlearning platform EdApp.
The Educate All programme calls for private enterprises, institutions and thought leaders to contribute free courseware on topics important to delivering the United Nations 2030 Agenda for...READ MORE
ApoGlyx closes 6 MSEK financing round
ApoGlyx is happy to announce that we have just closed a 6 million Swedish kronor investment round, coming from Almi Invest as well as from Swedish and Danish private investors. This new capitalwill allow us to progress our most advanced molecule to mandatory preclinical toxicology testing.
Furthermore, ApoGlyx has recently been accepted to
Supertrends experts provide insights on World Sepsis Day
Listen to the NLS2021 Life Science Day Rising Stars Award Winners
The CEO's of three Rising Stars Nordic Life Science Companies talk about their companies in an episode of The Scientific Podcasting Network Innovation by Innovators Series. You will hear SillaJonsdottir from Retina Risk, ApoGlyx CEO Michael Rützler, as well as Trude Tingvoll from RESPINOR.... READ MORE
APOGLYX WINS RISING STAR AWARD AT NORDIC LIFE SCIENCE DAYS 2021
SwedenBio, the organizer of Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry, today announced that APOGLYX is this year’s winner of theRising Star Award.... READ MORE
A new study shows enhanced survival of AQP9 knockout mice in edotoxemia
"Ablation of Aquaporin-9 Ameliorates the Systemic Inflammatory Response of LPS-Induced Endotoxic Shock in Mouse" has been published in Cells as part of the Special Issue Advances in Aquaporins and is available online.
A report by Supertrends on "Aquaporins and Sepsis" has been published
Supertrends has created a dynamic report on thetopic of AQPs and sepsis. Challenges in contemporary sepsis healthcare, as well as opportunities arising from AQP based therapies are discussed, and the report presents an outlook on the...READ MORE
RG100204 is effective in a preclinical model of bacterial sepsis
New ApoGlyx results demonstrate that RG100204 is effective in reducing organ damage in a preclinical model of bacterial sepsis.
There is currently no specific treatment for sepsis, the body’s overreaction to infection that often causes severe organ damage, and death. According to the Global Sepsis Alliance, 47 to 50...READ MORE
Finding elusive aquaporin inhibitors
Read a blog article by Jiqing Hansen on the story behind finding the long elusive aquaporin inhibitors
ApoGlyx patent applications granted in new countries
ApoGlyx has applied for two patents covering Aquaporin-9 inhibitor technology. A first patent has been granted in the USA in 2018, and in 2020 in Australia, China, and Japan. A second patent has also been granted in the USA in August 2020.